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P1
Angiotensin-converting enzyme in serum: false positives? 
A clinical case
Joana Clemente Duarte; Margarida Afonso; António Jorge Ferreira
Coimbra Hospital and University Center, Coimbra, Portugal 
Introduction: Angiotensin-converting enzyme in serum (ACES) is one 
of the key elements that increase the level of suspicion for the diagnosis 
of pulmonary sarcoidosis, a chronic systemic granulomatous disease of 
unknown origin, probably secondary to an abnormal immune response. 
Its association with lymphomas are described, including the description 
of „sarcoidosis-lymphoma syndrome” (SLS). There are few cases of SLS 
and the nature of this relationship is poorly characterized. 
Case report: A 47 year old woman with no medical history was being 
followed since 2012 for a pulmonary nodule that was stable, without lym-
phadenopathy associated. After three years, after a pneumonic process, a CT 
scan showed multiple mediastinal, supra-clavicular and lateral-cervical 
lymph nodes. Blood sample analysis revealed a high value of ACES. Auto-
immunity, protein profile, immunoglobulins and determination of calcium 
in the urine were normal. The patient was submitted to positron emission 
tomography, which revealed hypermetabolic lateral-cervical node and hilar 
involvement and underwent surgical removal of a supraclavicular node. The 
clinical pathology showed “gray area” lymphoma. Chemotherapy protocol 
was initiated and imaging control showed no lateral-cervical, mediastinal 
and hilar lymphadenopathy. She remains asymptomatic. 
Conclusions: Although this is not a typical case of “sarcoidosis-lymphoma 
syndrome” it highlights how increased levels of ACES may occur in these two 
diseases and lymphoma’s image can provide similar results as in pulmonary 
sarcoidosis. The clinicians should be aware that these pathologies can co-
exist and in some cases is still essential to achieve a correct histopathological 
diagnosis with implications in treatment, evolution and disease prognosis. 
P2
Sarcoidosis and veinous thromboembolic disease: about five 
observations
Frederic Riviere; Pierre Louis Conan; Herve Le Floch; Olivier Bylicki; 
Wanda Gaspard; France Charton; Jacques Margery
Percy military hospital, Clamart, France 
Introduction: Sarcoidosis, as chronic inflammatory disorders, is an 
unknow risk factor for veinous thromboembolic disease (VTED) 1, 2. 
Aim. For the first time, we are describing five observations of VTED 
associated with sarcoidosis. 
Material and methods: Retrospective analysis of the epidemiological, cli-
nical, radiological and biological data of patients who experienced a VTED 
(pulmonary embolism [PE] or deep vein thrombosis [DVT]) associated to 
histologically proved Sarcoidosis, previously or synchronously diagnosed. 
Results: 4 men and one woman, all of them Caucasians with a median age 
of 49 years old [46; 67] have showed 2 PE, 2 DVT and one combinaison of 
both. Two patients had a previous history of DVT. It was the first sign of the 
sarcoidosis for 4 cases out of 5. Three mediastinal- pulmonary sarcoidosis 
were stage 1 or 2, 1 had pulmonary and cardiac involvement and one neu-
rosarcoidosis. They were considered to be relatively inactive: lymphocytes 
1128/mm 3 [918; 1470], gammaglobulineaemia 9.2 g/L [8.7; 10.5], calciuria 
2.21 mmol/day [2.11; 6.23] and no volume restriction nor airflow obstruction 
with a median FEV1/FVC of 78. 81%. Three patients presented another VTED 
when anticoagulants were discontinued and all of them were evolving to-
ward a chronical sarcoidosis without refractory cases. They weren’t showing 
another VTED risk factor3 and thrombophilia search was negative. Activity 
markers like chitotriosidase or neopterin weren’t performed. 
Conclusions: Even if relative risk is low4, sarcoidosis might be considered 
as a risk factor for VTED. 
P3
Langerhans cell histiocytosis: variability  
in pulmonary involvement
Joao Silva; Tito Abrantes; Marta Sousa; Vitor Melo; Antonio Reis; 
Ana Campos; Simoes Torres
Centro Hospitalar Tondela-Viseu, Viseu, Portugal 
Introduction: Langerhans cell histiocytosis (LCH) or histiocytosis X, is 
a rare disorder characterized by an abnormal increase in histiocyte cells, 
components of the immune system. Signs of LCH depend on the extent and 
location of the disease. A male predominance is observed. Clinical cases The 
author presents two clinical cases with distinct pulmonary involvement. 
Case 1: 18 year-old male, smoker, with chronic dry cough and acute 
chest pain. Computed tomography (CT) of the chest showed exuberant 
pulmonary cysts, diffusely distributed with a  predominance in the 
lung apices, unequal size and bizarre shapes. Bronchofibroscopy with 
bronchoalveolar lavage was negative to CD1a cells, but lung biopsy 
established the diagnosis. 
Case 2: 19 year-old male, non-smoker, with sudden dyspnea and pleuritic 
chest pain. Chest x-ray pointed out left spontaneous pneumothorax, 
which wasn’t solved with thoracic drainage. He has undergone cirur-
gical pleurodesis with blebs resection whose pathological report was 
compatible with LCH. Thorax CT identified only small cystic lesions in 
the right pulmonary apex. 
Conclusions: In adults with LCH, the pulmonary system is the most frequ-
ently involved organ and pulmonary lesions may be the only manifesta-
tion. The clinical spectrum is broad. Image studies can reveal from diffuse 
cystic lesions, nodular infiltrates, pleural effusion and pneumothorax to 
minimal changes of the parenchyma. 
P4
Sarcoidosis incidence and prevalence: a nationwide register-
based assessment in Sweden
Elizabeth V. Arkema; Johan Grunewald; Susanna Kullberg; 
Anders Eklund; Johan Askling
Karolinska Institutet, Stockholm, Sweden 
Aim: To estimate the contemporary incidence and prevalence of sarcoido-
sis using Swedish national population-based register data. 
Material and methods: Adults with any visit listing an ICD code for 
sarcoidosis were identified from the National Patient Register (hospitali-
zations 1964−2013 and outpatient care 2001−2013). Demographic and 
medication dispensing data were retrieved from national registers. We 
estimated the prevalence of sarcoidosis in 2013 overall and by county 
of residence. Incident sarcoidosis 2003−2012 was estimated overall, by 
sex, age, education level and year of diagnosis. Definitions of incident 
and prevalent cases were varied to test the robustness of our results. 
Results: Over 16, 000 people had a history of sarcoidosis in 2013. When 
defined as 2 sarcoidosis-coded visits, the prevalence was 160/100, 000. 
Using different definitions, the prevalence ranged from 152 (requiring 
a  specialist visit) to 215/100,000 (only 1 visit required). The highest 
prevalence was observed in northern less population-dense counties. There 
were over 10, 000 incident cases between 2003 and 2012. The incidence 
was 11.5/100,000 per year and varied by −10% to +30% depending on 
case definition. The incidence was highest in males 30−50 years old and 
in females 50−60 years old but did not differ by education level and was 
stable over time. 
Conclusions: This study represents the largest epidemiological inve-
stigation of sarcoidosis using population-based individual-level data. 
Sarcoidosis occurrence was stable over time but varied substantially by 
geographical region, age and sex. The age at onset was 10 years younger 
in males than in females. 
Pneumonologia i Alergologia Polska 2016, vol. 84, Supplement III, pages 1–14 
www.pneumonologia.viamedica.pl2
P5
Antisynthetase syndrome: case series of a rare condition
Joana Clemente Duarte; Margarida Afonso; Sara Freitas; Tiago Alfaro; 
Carlos Robalo Cordeiro
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal 
Introduction: The antisynthetase syndrome (ASS) is a rare auto-immune 
disorder characterized by a variable association between antisynthetase 
antibodies and interstitial lung disease, myositis, arthritis, fever, Ray-
naud’s phenomenon and mechanic’s hands. Pulmonary involvement, 
when present, is the main prognosis determinant. AIM: Our objective was 
to characterize the ASS population under the care of an interstitial lung 
disease (ILD) clinic in a university hospital in Portugal. 
Material and methods: We performed a  retrospective analysis of all 
ASS cases attending our clinic between 2006 and 2015. Patients were 
identified through a  search of the clinical database. We collected 
data on complaints, lung function, imaging, laboratory, treatment 
and prognosis. 
Results: A total of six patients (five female and one male) were included, 
with a median age of 58 years. All were white, with a median age at diagnosis 
of 50 years. Most presented for systemic complaints, including asthenia and 
myalgia. One had skin lesions. None of the subjects had neurological or 
cardiac involvement. Lung function was normal in three, while the others 
had mild restriction with low diffusion capacity. On chest imaging, half 
showed predominant ground glass infiltrates, and half had predominant 
fibrotic changes. All received chronic steroids, with concomitant azathio-
prine in most. Upon dose reduction, four patients had symptom relapse. No 
deaths were registered during a median follow-up of 48 months. 
Conclusions: In our patient population, ASS affected mostly white middle 
aged females. There was a good clinical response to treatment, but a high 
rate of relapse upon reduction of steroids. 
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Fatal arrhythmic events in patients with cardiac sarcoidosis; 
retrospective cohort analysis of Japan
Kengo Kusano1; Yusuke Hattori1; Kohei Ishibashi1; Teruo Noguchi1; 
Toshihisa Anzai1; Satoshi Yasuda1; Hisao Ogawa1; Fumio Terasaki2; 
Mitsuaki Isobe3
1National Cerebral and Cardiovascular Center, Suita, Japan; 2Osaka 
Medical College, Takatsuki, Japan; 3Tokyo Medical and Dental University, 
Tokyo, Japan 
Introduction/Aim: Sarcoidosis is a systemic non-caseating granulomatous 
disease of unknown etiology. Cardiac involvement (cardiac sarcoidosis, CS) 
has been reported to be an important prognostic factor and corticosteroid 
is usually used to prevent deterioration of cardiac function and fatal ar-
rhythmia. We evaluated the long-term prognosis in patients with CS from 
Japanese Multi-Center retrospective cohort analysis. 
Material and methods: Total of 746 Japanese patients from 56 hospitals 
who diagnosed CS were examined. Patients who unsatisfied the criteria for 
cardiac sarcoidosis proposed by the Japanese Society of Sarcoidosis and 
Other Granulomatous disease (JSSOG) modified in 2006 were excluded, 
and 438 patients (135 males, mean age of 59.7 ± 12.1 years old, and mean 
follow-up period of 5.6 ± 4.7 years) were analyzed. The relationship of 
cardiac function (left ventricular ejection fraction: LVEF) and later adverse 
events were evaluated. 
Results: Corticosteroid (mean dose of 7. 2 mg) was prescribed in 382 of 
CS patients (87.2%) and total 97 adverse events (22.1%) were observed 
(all-cause death in 52 and appropriate implantable cardioverter defibril-
lator (ICD) discharge in 59 patients). Kaplan-Meier analysis revealed that 
the fatal arrhythmic events (sudden death and appropriate ICD discharge) 
were more observed in moderate or low LVEF by initial echocardiography 
(log-rank p < 0.02). This observation was also observed in patients without 
prior ventricular arrhythmia. 
Conclusions: This large scale Japanese multi- center data showed that initial 
LVEF was a strong predictor of fatal arrhythmic events in CS, therefore ICD 
implantation as a primary prevention would be needed even after starting 
corticosteroid in patients with decreased cardiac function. 
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Reactivation inflammation impacts on the ventricular arrhythmia 
for the patients with cardiac sarcoidosis
Kenzaburo Nakajima1; Ikutao Nakajima2; Kohei Ishibashi1;  
Tsukasa Kamakura1; Mitsuru Wada1; Yuko Inoue1; Koji Miyamoto1; 
Takashi Noda1; Takeshi Alba1; Shiro Kamakura3; Kengo Kusano1
1National Cardiovascular Center, Osaka, Japan; 2St. Marianna medical 
university, Kawasaki, Japan; 3National Cardiovascular Centerati, Osaka, 
Japan 
Introduction: Cardiac sarcoidosis (CS) sometimes developed lethal ven-
tricular arrhythmia (VA). The relationship between reactivation of inflam-
mation after steroid therapy and VA in patients with CS is still unclear. 
Material and methods: Data on 121 CS patients with reduced LVEF and 
steroid therapy were enrolled. The inflammation status was evaluated by 
cardiac-positron emission tomography and Gallium-shintigraphy every 
6 months. We evaluated relationships with reactivation of inflammation 
and VA events. 
Results: During a median follow-up of 1418 days, 25% of patients sho-
wed reactivation of inflammation. VA events were significantly higher in 
patients with reactivation than others (p < 0. 01). Interestingly, the type 
of VA manifestation was different and ventricular fibrillation was more 
common in patients with inflammation reactivation. 
Conclusions: Reactivation of inflammation in patients with CS is a highly 
risk of ventricular arrhythmia. 
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Clinical value of HRCT scores in newly diagnosed pulmonary 
sarcoidosis
Regina Aleksoniene1; Ingrida Zeleckiene2; Mindaugas Mataciunas2; 
Roma Puronaite3; Edvardas Danila1
1Clinic of Infectious, Chest diseases, Dermatovenereology and 
Allergology, Vilnius University, Vilnius University Hospital Santariskiu 
klinikos, Center of Pulmonology and Allergology, Vilnius, Lithuania; 
2Vilnius University Hospital Santariskiu klinikos, Radiology and Nuc-
lear medicine Center, Vilnius, Lithuania; 3Vilnius University Hospital 
Santariskiu klinikos, Center of Informatics and Development, Vilnius, 
Lithuania 
Aim: To evaluate the significance of high-resolution computed tomography 
(HRCT) scores and impairment of pulmonary function in different radio-
logic stages of sarcoidosis patients. 
Material and methods: 80 patients with newly diagnosed sarcoidosis 
(41 F, 39 M; age 39 ± 9 yrs) were included. Patients underwent HRCT 
scanning and pulmonary function tests (PFT). HRCT scores and PFT 
values were analyzed. 15 (19%) of patients had stage 1, 59 (74%) — 
stage 2, and 6 (7%) — stage 3. 
Results: Micronodules (77.5%), macronodules (53.8%) and linear 
opacities (45%) were most frequently met patterns in HRCT of 
patients with pulmonary sarcoidosis. Only the number of micro-
nodules was significantly higher (p = 0.004) in stage III compared 
with other stages. 
Statistically significant differences between FVC (p = 0.040), FEV1 
(p = 0.017), TLC (p = 0.049), VC (p = 0.015), DLCO (p = 0.012) were 
found in different radiographic stages of sarcoidosis. PFT values were 
decreased in stage 3 compared with stage 1 patients. 
Significant correlations between consolidation score on HRCT and 
FVC (r = −0. 227, p = 0. 043), FEV1 (r = −0.299, p = 0.007), FEV1/FVC 
(r = −0.245, p = 0.029) as well as correlation between ground glass 
opacities score and DLco (r = −0.267, p = 0.017) were established. 
We did not found significant correlations between micronodules or 
macronodules score and PFT indices. 
Conclusions: A  strong  interface between radiologic changes and 
pulmonary function impairment exists in sarcoidosis patients. Con-
solidation and groud glass opacities HRCT scores, but not micronod-
ules or macronodules scores correlated negatively with pulmonary 
function indices. However, overall clinical value of HRCT scores 
was not very high. 
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Telomere shortening in type II pneumocytes relates to idiopathic 
pulmonary fibrosis
Aernoud van Batenburg1; Reinier Snetselaar1; Roel Goldschmeding2; 
Tri Nguyen2; Matthijs van Oosterhout1; Karin Kazemier1; Jan Grutters1; 
Coline van Moorsel1
1St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands; 2UMC 
Utrecht, Utrecht, The Netherlands 
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a  devastating 
disease with a  median post-diagnostic survival of approximately 
4 years. Recently it has been discovered that telomere length (TL) 
maintenance plays a key role in IPF. In patients with different types of 
pulmonary fibrosis, shortening of leukocyte telomere length was found, 
especially in telomerase mutation-related disease. In this pilot study, 
we measured TL in the regenerating cells of lung alveoli, so-called 
type II pneumocytes. These cells are considered to be the crucial cell 
type in IPF pathogenesis. 
Material and methods: Tissue slides of sporadic IPF patients and con-
trols were stained using telomere Fluorescence In Situ Hybridization 
(FISH). Type II cells were identified using the proSPC antibody from 
Merck Millipore (ab3786, Rabbit 1: 300). Subsequently, quantification 
of telomere fluorescence was measured per cell type, discriminating 
between type II and all the surrounding cells combined. These were 
classified as non-type II cells. 
Results: Type II pneumocyte TL was significantly shorter in fibrotic 
areas compared to non-fibrotic areas or control tissue (p-values of 0.004 
and 0.0023 respectively). In non-type II pneumocytes TL did not differ 
between fibrotic and non-fibrotic areas. Furthermore, within controls 
no differences were observed between type II cells and non-type II cells. 
Conclusions: In conclusion, the co-localization of short telomeres in 
type II cells and the pathophysiology of IPF suggests that telomere 
shortening plays a  critical role in the fibrotic remodeling of lung 
tissue in this disease. 
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Airway-centered interstitial fibrosis — rare interstitial lung 
disease: 2 case reports
Vitor Melo; Marta Sousa; Joao Silva; Tito Abrantes; Ana Campos; 
Simoes Torres
CHTV, Viseu, Portugal 
Airway-centered interstitial fibrosis (ACIF) is a new and rare interstitial 
lung disease (ILD) of unknown cause characterized by chronic cough 
and progressive dyspnea; history of inhaled exposure; propensity 
for women; occurrence in middle age; progressive peribronchiolar 
distribution of interstitial inflammation and fibrosis with bronchiolar 
metaplasia distinct from any form of ILD or idiopathic interstitial 
pneumonia (IIP). The majority of patients are non-responsive to corti-
cotherapy with poor prognosis. We describe 2 female patients, 65 and 66 
years old, presenting with chronic dry cough and progressive dyspnea. 
Both non-smokers, farmers and with a history of inhaled exposition to 
birds. Chest radiographs revealed diffuse reticulonodular infiltrates 
and bronchial walls thickening. ChestCT showed reticular fibrosis and 
ground glass infiltrates across the pulmonary fields in one and sparing 
the upper on the other. Bronchoalveolar lavage showed a small increase 
in lymphocytes/neutrophils in one, the ratio CD4/CD8 < 1 in both. 
The diagnosis was made by surgical biopsy revealing pericentrilobular 
lesions and linfoplasmocitary infiltrate compatible with ACIF. Both 
patients began systemic corticotherapy for 12 months. In one case the 
disease progressed with worsening symptoms, pulmonary functional 
tests and CT imaging even after starting combined imunosuppression 
with Azathioprine. The other patient improved with less symptoms and 
decreased area of disease on the CT image. These 2 cases presented 
similar clinical, radiological and pathological features as most of the few 
cases reported in literature. Our patients were non-smokers but were 
exposed to birds. The evolution varied with one improving after the-
rapy and the other progressing even after combined imunosupression. 
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Clarithromycin decreases IL-6 concentration in serum and BAL 
fluid in patients with cryptogenic organising pneumonia
Elżbieta Radzikowska; Adriana Roży; Paulina Jaguś;  
Małgorzata Polubiec-Kownacka; Joanna Chorostowska-Wynimko; 
Kazimierz Roszkowski-Śliż; Elżbieta Wiatr
National Tuberculosis and Lung Diseases Research Institute, Warsaw, 
Poland 
Introduction: Inflammatory cytokines are involved in the development 
of cryptogenic organising pneumonia (COP). It was shown, that macroli-
des inhibited the cytokines production in alveolar macrophages of COP 
patients. Objectives: Assessment of interleukin 1b (IL-1b), IL-6, IL-8, and 
transforming growth factor b (TGF-b) concentrations in serum, and in BAL 
fluid (BAL-f) in COP patients treated with clarithromycin. 
Material and methods: 26 patients with biopsy proven COP (18 women and 
8 men), in a mean age of 56. 46 ± 8. 83 years were enrolled into the study. 
Complete response was achieved in 22 patients and four patients did not 
respond to treatment. ELISA method was used to measure the serum and 
BAL-f concentrations of IL-1b, IL-6, IL-8, and TGF-b. 
Results: Before treatment the serum IL-1b1, IL-6, IL-8, and TGF-b1 
concentrations were similar in responders and non- responders. 
Significant decrease of IL-6 [8. 98 ± 13. 26 pg/mL vs. 3. 1 ± 6.95 pg/
mL; p = 0.005) ], IL-8 [20.14 ± 25.72 pg/mL vs. 10.14 ± 6.8 pg/mL; p 
= 0.007], and TGF- b1 [37.89 ± 12.49 ng/mL vs. 26.49 ± 12.45 ng/mL; 
p = 0.001] serum concentration, and IL-6 concentration [30.56 ± 56.78 
pg/mL vs. 4. 53 ± 5.84 pg/mL; p = 0.036) ] in BAL-f was noticed after 
clarithromycin (CAM) treatment. Clarithromycin treatment resulted 
in significantly lower mean value of IL-6 in serum in responders than 
in non- responders. 
Conclusions: Response to clarithromycin treatment was associated with 
decrease of IL-6, IL-8, and TGF-b1serum concentrations, and IL-6 concen-
tration in BAL-f. 
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Results of clarithromycin treatment in patients with cryptogenic 
organising pneumonia
Elżbieta Radzikowska; Elżbieta Wiatr; Dariusz Gawryluk;  
Renata Langfort; Iwona Bestry; Joanna Chorostowska-Wynimko; 
Kazimierz Roszkowski-Śliż
National Tuberculosis and Lung Diseases Research Institute, Warsaw, 
Poland 
Introduction: Despite that corticosteroids have been established as the 
standard treatment of cryptogenic organising pneumonia (COP), other 
drugs such as clarithromycin (CAM), are also proved as effective. The 
goal of this study was to present the results of CAM versus prednisone 
(PRE) treatment in patients with biopsy-proven COP. 
Material and methods: From 1999 to 2014, 44 patients were treated 
with CAM (500 mg twice daily orally, for 3 months) and 32 with PRE 
(mean initial dose of 0. 73 ± 0.24 mg/kg/d for a mean of 8. 68 ± 4.08 
months). 
Results: The clinical presentation, laboratory, and radiological findings 
did not differ significantly between patients treated with CAM and PRE, 
with the exception of a higher frequency of sweats, ground glass opacities, 
and migratory pattern of lesions, and fewer cases of FEV1 of < 80% and 
hypoxemia among patients treated with CAM than with PRE. A complete 
response was achieved in 39 (93%) patients treated with CAM and in all 
treated with PRE. Relapse was noted more frequently in patients treated 
with PRE than with CAM (53% vs. 7%; p < 0.0001). Adverse events were 
noticed in 53% of patients treated with PRE and 2% treated with CAM. 
FVC > 78% of predicted with sensitivity — 79% and specificity-80%, 
and FEV1 > 63% of predicted with sensitivity −97% and specificity — 
60% identified patients who were good candidates for CAM treatment. 
Conclusions: CAM can be used as an alternative treatment of COP, but in 
patients with pulmonary function parameters within the normal limits. 
This therapy is shorter, better tolerated, and associated with fewer adverse 
events and relapses than PRE. 
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Chronic hypersensitivity pneumonitis: implications of usual 
interstitial pneumonia pattern in disease severity
Eva Padrao; Vanessa Santos; Patricia Mota; Natalia Melo; Rui Cunha; 
Jose Miguel Pereira; Antonio Morais
Centro Hospitalar de Sao Joao, Porto, Portugal 
Introduction: Chronic hypersensitivity pneumonitis (cHP) has a wide 
variable clinical presentation and evolution, and there is a subGroup 
of patients with usual interstitial pneumonia pattern (cHP/UIP) which 
information is scarce. 
Aim: Characterization of patients with cHP, comparing cHP/UIP with 
other cHP. 
Material and methods: Analysis of cPH patients with disease behaviour 
stratified according with ATS/ERS classification for IIP. HRCT fibrosis 
score was used for quantification of disease extent in cHP/UIP patients. 
Results: Included 86 patients with mean (± SD) age of 61.5 (± 14) 
years, 66.3% (n = 57) female. Most (84.5%) were never smokers. Al-
most half (48.8%) had cHP/UIP, with an average fibrosis score of 8.4 
(± 2.8). Patients with cHP/UIP had significantly lower DLCO [44.5 
(± 18.5)% vs. 57 (± 21.5)%, p = 0.015] and lymphocytosis [27.1 (± 
22.6)% vs. 45 (± 19.6)%, p = 0.001]. Regarding disease behaviour in 
cHP/UIP, 9.1% had stable disease (vs. 31.8% in other cHP), 45.5% had 
progressive, irreversible disease with potential for stabilization (vs. 
38.6% in other cHP) and 45.5% had progressive, irreversible disease 
despite therapy (vs. 29.5% in other cHP). Therapeutic approach included 
steroids and immunosuppressants in 62.2%, only steroids in 21.6% and 
16.2% didn’t make any anti-inflammatory therapy, without relevant 
differences between Group s. Fourteen patients were referred for lung 
transplantation, 8 with cHP/UIP. During the follow-up, 24.4% died, with 
a median survival significantly lower in cHIP/UIP (106 vs. 154 months, 
p = 0.023). 
Conclusions: cHP showed a wide variability in disease severity, standing 
out the Group with cHP/UIP in whom an unfavourable evolution occu-
rred despite therapy. At diagnosis, this subGroup presented a greater 
functional severity and may require higher monitoring and therapeutic 
approach. 
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Addition of EBUS-TBNA to bronchoscopic biopsies in the 
diagnosis of sarcoidosis
Zora Pavlović-Popović; Bojan Zarić; Milana Panjković; Dušan Belić; 
Ana Jakić
The Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, 
Serbia 
Introduction: While the utility of endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS- TBNA) has been reported in 
providing sarcoidosis diagnosis, its performance in compunction with 
other bronchoscopic sampling methods remains to be clarified. Aims to 
evaluation the sensitivity of different diagnosis modalities (EBUS-TBNA, 
transbronchial biopsy-TBB, endobronchial biopsy-EBB) performed during 
the same endoscopic procedure for confirming sarcoidosis. 
Material and methods: We retrospectively reviewed the data of 64 patients 
(20 men, 44 women), Ø 46 year old (range 31−69) in whom the suspected 
initial diagnosis of sarcoidosis had been supported by confirmation of 
granulomas. The diagnostic yield of the three bronchoscope sampling 
(EBUS-TBNA, TBB, EBB) between January 2012 and December 2015 in 
our Institute. 
Results: According to radiologic CXR stages were: stage I 47%, stage II 
34%, stage III 19%. Bronchoscopy with EBB was performed in 39/64, 
TBB in 55/64 and EBUS-TBNA of mediastinal and hilar lymph nodes 
49/64. Confirmation of granulomas was achieved in 39% of EBB (regar-
dless of macroscopic appearance), 80% of TBB and 66% of EBUS-TBNA. 
According to radiological stages (I vs. II) the diagnostic yield was: EBB 
40% vs. 42%, TBB 30% vs. 92%, EBUS-TBNA 82% vs. 71%. There were 
4 post-interventional pneumothoraxes. 
Conclusions: EBUS-TBNA with combined samplings should be considered 
as a  first diagnostic procedure in sarcoidosis stage I, but TBB seems to 
remain the better option for stage II disease. 
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Clinical features of usual intertitial pneumonia — correlation 
between idiopathic pulmonary fibrosis and connective tissue 
disease associated with usual interstitial pneumonia
Zora Pavlović-Popović; Bojan Zarić; Marija Vukoja; Milana Panjković; 
Dragan Dragičić; Ana Jakić
The Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia 
Introduction: The study objective is to compare the clinical feature of IPF 
and UIP-CTD to address the clues for predicting the underlying situation. 
Material and methods: A retrospective analysis of HRCT diagnosed UIP patients 
between 2004−2014 included demographic features, smoking habits, symptoms 
and signs, serology, pulmonary function and dominant radiology findings 
and selected treatment were compared between of IPF and UIP-CTD Group s. 
Results: The total of 103 UIP patients (62 IPF and 41 UIP-CTD) were analy-
sed. Most in the CTD patients had rheumatoid arthritis (n = 21), systemic 
sclerosis (n = 11), Sjögren syndrome (n = 8), systemic lupus erythematosus 
(n = 2), and polymyositis (n = 1). The IPF Group included 65% of males, 
while females made 60% of the UIP- CTD Group. The patients mean age was 
significantly different in the IPF and UIP-CTD Group −65.79 ± 10.15 vs. 
60.0 ± 12.98. Smokers made 59% and 27% of the IPF and UIP-CTD Group 
respectively. IPF Group had severer and longer lasting symptoms, dyspnoea 
and cough, as well as the mean mMRC dyspnoea score. Clubbing was more 
frequently registered in IPF patents (39% vs. 19%). Autoantibodies were 
positive in 35% of IPF patients (RF, ANA). In IPF Group had lower mean 
DLco, TLC and RV. The only radiological findings were significantly diffe-
rent in the two Group s, presented with honeycomb lungs in 87% and 45% 
of the IPF and UIP-CTD Group respectively. Immune suppressive treatment 
was more commonly administered in the UIP-CTD Group (81% vs. 52%). 
Conclusions: In the patients with UIP pattern in HRCT, IPF was most 
frequently diagnosed in older smoking males with clubbing. Autoantibo-
dies are of no use in differentiating between IPF and CTD patients. IPF 
patients might be diagnosed lately since those patients mostly have a longer 
history of symptoms, reduced lung volumes and diffusion capacity, and 
more common honeycombing in HRCT. Typical extrapulmonary symptoms 
could alert physicians to investigate CTD or in CTD patients pulmonary 
symptoms may lead to investigate pulmonary involvement. 
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The concept of organizing pneumonia — as a pathologic term
Fatma Tokgoz Akyil1; Tulin Sevim1; Aysun Kosif Misirlioglu2;  
Meltem Coban Agca1; Mustafa Akyil2; Ayse Alp Arsev3; Murat Kavas1
1Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research 
Hospital, Department of Chest Diseases, Istanbul, Turkey; 2Sureyyapasa Chest 
Diseases and Thoracic Surgery Training and Research Hospital, Department 
of Thoracic Surgery, Istanbul, Turkey; 3Sureyyapasa Chest Diseases and 
Thoracic Surgery Training and Research Hospital, Pathology, Istanbul, Turkey 
Introduction: Organizing pneumonia (OP) is a histopathological term 
describing patchy filling of the lung alveoli and respratory bronchioles by 
loose plugs of granulation tissue. OP term may describe mainly OP disease 
or may be seen in association with another disease such as malignancy, 
infections. In present study, we investigated the clinical reflection of lesions 
defined as OP histopathologically. 
Material and methods: Between 2011−2015, all lung pathology reports 
including the term’organizing penumonia’were included. All patients’; 
medical files were examined. OP were classified as reactive OP (adjacent 
to another predominant disease) and OP disease. The demographic, ra-
diological and clinical findings were recorded. Radiological findings were 
Group ed as typical, focal and infiltrative. 
Results: Among 6352 lung pathology reports, 138 reports were included. 
Thirty-four (25%) were female and the mean age was 54 ± 14. Six of the 
biopsies were transbronchial biopsy materials. 75 (54%) of the biopsies were 
right-lung sided. 84 (61%) of the patients were classified as reactive OP, 
54 (39%) as OP disease. The most frequent reactive process was seen with 
malignancy (66%), mostly squamous cell carcinoma. The other diseases 
were bronchiectasis, lung abscess, tuberculosis, cyst hydatic, hypersen-
sitivity pneumonia, bullae, etc. Forty-eight (89%) patients with OP disease, 
were diagnosed as COP. Radiological findngs were consistent with focal OP 
mostly (n = 34,63%). In PET-CT scans FDG uptake was high in focal forms. 
ABSTRACTS
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Conclusions: OP, as a histopathologic term, is included in pathology reports 
describing reactive processes. Cryptogenic OP is more frequent than secon-
dary forms. Radiologicallly focal OP is more often than the other forms. 
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The clinical course of organizing pneumonia
Fatma Tokgoz Akyil; Emine Aksoy; Armagan Hazar; Sumeyye Bekir; 
Sinem Güngör; Murat Kavas; Aylin Güngör; Tulin Sevim
Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research 
Hospital, Department of Chest Diseases, Istanbul, Turkey 
Introduction: The clinical presentation and clinical course of OP is quite 
variable. In present study, we investigated the clinical, radiological findings 
of OP patients and investigated the clinical courses. 
Material and methods: The present study is a retrospective cohort study, 
conducted in a chest disease teaching hospital between 2005−2015. Pa-
tients diagnosed and followed as OP in our hospital were included. The 
clinical courses were categorized as progressive, relapse, non-relapse and 
the predictive factors for relapse were investigated. 
Results: 19 (41%) were male and The mean age was 54 ± 14. The most com-
mon presenting symptoms were shortness of breath and cough. Twenty-five 
patients had no additional diseaes, 14 had never smoked. Radiological classi-
fication was consistent with typical OP in 31 (67%), focal in 7 and infiltrative 
in 8. The median follow-up duration was 18 (1−108) months. For treatment, 
steroid were used. Five patients had required intensive care unit follow-up 
due to respiratory failure and 3 of whom died within 2 months. Of the other 
43 patients’, 18 (39%) had at least one relapse. Median relapse duration was 
7 months and 16 of them were re-treated with steroids. Two patients were 
decided to be treated life-long low-dose steroids for recurrent relapses. When 
the baseline parameters were investigated for relapse, demographics, smoking 
status, additional diseases, spirometric values, serum albumin, LDH values, 
cryptogenic or secondary forms, leucocyte, SaO2 did not increase relapse 
risk. Lower levels of baseline hemoglobin (p = 0.043) and higher levels 
of bronchoalveolar lavage eosinophils (p = 0.043) increased relapse risk. 
Conclusions: OP is mostly benign whereas rapidly-progressive courses may 
be seen. Lower baseline levels of hemoglobin and higher BAL eosinophils 
may predict relapsing forms. 
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Introduction: Sarcoidosis is a disease, which may be characterized by 
alveolitis and granuloma formation and result in fibrosis, and in the 
case of which spontaneous remissions may be observed as well. A test 
that, at the time of diagnosis, provides information about prognosis and 
enables the anticipation of the disease’s likelihood of becoming chronic 
would be expedient. Mean platelet volume (MPV) and neutrophil-to-lym-
phocyte ratio (N/L) or Trombocyte-to-MPV ratio, which are readily and 
practically detectable currently, are such reagents, the prognostic signi-
ficance of which have been proved for numerous inflammatory diseases. 
Objective: The objective of this study is to establish the significance 
of inflammatory reagent values at the time of initial hospital application 
of patients with sarcoidosis for the anticipation of the disease’s likelihood 
of becoming chronic. 
Material and methods: Some 142 of 384 cases followed up at our clinic, 
records for which have been maintained regularly for minimum two years 
from the relevant date of diagnosis, for which medical treatment has not 
been applied, and which are not at phase 0, were included to the study 
universe. The files of the patients were examined, and demographic deta-
ils, relevant disease phase, mortality, follow-up period and inflammatory 
reagents (ACE, CRP, neutrophil, lymphocyte, trombocyte, MPV, N-to-L 
ratio, absolute N-to-L ratio and Trombocyte-to-MPV ratio) of the same 
were recorded. The cases in the study universe were Group ed into two 
with respect to the respective radiological healing progress; Group 1: The 
patients, in whose radiological findings no change was detected at the end 
of the two year period (chronic Group ); Group 2: The patients, in whose 
radiological findings total remission was observed at the end of the two 
year period (remission Group). 
Results: Group 1 was comprised of 86 cases (Median age: 47, F/M: 67/19), 
while Group 2 was comprised of 56 cases (Median age: 42, F/M: 45/11). The 
N-to-L ratio was detected to be 2.80 + −1.32 for Group 1 and 2. 45 + −1.62 
for Group 2. It was observed that the LEN, N-to-L ratio and absolute N-to-L 
ratio of Group 2 was significantly lower than those of Group 1 (p < 0.05). 
Any significant difference was not established between the cases in Group 1 
and those in Group 2 in terms of the other parameters (p > 0.05). The average 
follow-up period was established to be 65 months for Group 2 and 84 months 
for Group 1. The follow-up period for the patients in Group 1 was significantly 
longer than that for the patients in Group 2 (p = 0.016). 
Conclusions: High values measured for the said reagents at the time of diagno-
sis in sarcoidosis cases can be considered as indicators suggesting delay in the 
remission of the patient, and can be used for the close follow-up of the patients. 
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Introduction: Sarcoidosis may involve multiple organs or systems, among 
which lungs happen to be the most frequently involved organs. Researches 
on extrapulmonary involvement are of crucial importance for the monito-
ring and treatment of the patient. While, under treatment, the pulmonary 
lesions heal, the activity may continue in extrapulmonary organs, and the 
disease may even progress. Certain serum reagents (IL-18, sIL2R) come to 
the fore for their ability to indicate extrapulmonary involvement. The num-
ber of publications studying the use of Neutrophil-to-/lymphocyte (NLR) 
and Platelet-to-lymphocyte ratios, which are easily accessible at affordable 
costs, for the purpose of prognosis determination as a part of differential 
diagnosis has been increasing recently. Objective: The objective of this study 
is to research on the significance of the inflammatory reagent values of the 
sarcoidosis patients at the time of the initial hospital applications thereof 
in the determination of the extrapulmonary involvement. 
Material and methods: 142 cases, which are followed up at our clinic and 
the extrapulmonary involvement of which have been studied, were included 
to the study universe. The files of the patients were examined, and the 
demographic details, disease phase, extrapulmonary involvement presence 
and inflammatory reagents (ACE, neutrophil, lymphocyte, trombocyte, MPV, 
NLR, NLR absolute, Trombocyte-to-MPV ratio) of the same were recorded. 
The cases were Group ed into two with respect to the extrapulmonary 
involvement presence;Group 1: no extrapulmonary involvement presence, 
Group 2: extrapulmonary involvement presence. 
Results: Group 1 was comprised of 98 patients (Average of age: 44 ± 12, F/M: 
77/21), while Group 2 was comprised of 44 patients (Average of age: 44 ± 
11, F/M: 36/8);and while there were 103 patients at phase 1, there were 33 
at phase 2 and 6 at phase 3. While Group 1 included 70 phase 1, 23 phase 2 
and 5 phase 3 cases; Group 2 included 31 phase 1, 12 phase 2 and 1 phase 
3 patients. The extapulmonary involvements observed in 44 patients were 3 
eye involvements, 13 skin involvements and 3 heart involvements, respec-
tively. The number of cases with double organ involvement was 12, while 
the number of triple organ involvement was 1. Any significant difference 
was not found amongst the cases in terms of ACE, neutrophil, lymphocyte, 
trombocyte, MPV, NLR, NLR absolute, Trombocyte-to-MPV ratio, being the 
reagents studied (p > 0.05). 
Conclusions: The outcomes of the study reveal that ACE, neutrophil, lym-
phocyte, trombocyte, MPV, NLR, NLR absolute, Trombocyte-to-MPV ratio, 
being the inflammatory reagents studied, are not indicative in respect to 
the researches on the extrapulmonary organ involvement. 
P20
Thyroid sarcoidosis: a case report
Sümeyye Alparslan Bekir1; Sinem Agca Altunbey1; Murat Yalcinsoy2; 
Firuzan Aytar1; Çagatay Tezel3; Selahattin Oztaş1; Hatice Türker1
1Süreyyapaşa Pulmonary Disease Training and Research Hospital, 
Istanbul, Turkey; 2Inönü University School of Medicine, Malatya, Turkey; 
3Süreyyapaşa Pulmonary Disease Training and Research Hospital, Istanbul, Tukey 
Introduction: Sarcoidosis is a multisystemic disease with unknown etiology 
and it is characterized by non-caseating granuloma. Thyroid involvement 
of sarcoidosis is very rare and was first identified in 1938. The frequency 
of thyroid involvement in sarcoidosis cases was reported to be 4% based on 
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autopsy studies. In this report, we aimed to describe a rare case of thyroid 
involvement in sarcoidosis under the light of current literature. 
Case: 54-years old female patient referred with the complaint of cough. Skin exa-
mination showed nodular lesions on the exterior skin of both arms. Hemogram 
and biochemistry parameters were within normal range. Lung X-ray showed 
bilateral hilar lymphadenopathy (BHL), fullness in right paratracheal region 
and density increase in right paracardiac region. Thorax CT showed bilateral 
nodules in thyroid glands, multiple mediastinal LAPs, BHL and bronchiectasis 
in the right middle lobe. In FOB, extensive millimetric mucosal nodules were 
detected in the bronchial mucosa of the intermediate and middle lobes. THNAB 
was initially performed from the main carina towards subcranial LAP, and then 
biopsy samples were obtained from the nodules by a forceps. Pathological dia-
gnosis was reported as granulomatous inflammation with small necrotic foci. 
Skin biopsy revealed tuberculoid granuloma with central necrotic foci. Due to 
the thyroid lesion seen on thorax CT, left thyroidectomy and mediastinoscopy of 
the mediastinal lymph nodes were performed. Pathological examination of both 
tissues confirmed granulomatous inflammation with focal necrosis. Advanced 
investigations were performed for differential diagnosis. ACE was 47U/L, PPD 
was negative and PFT was found to be within normal range. Ophthalmology 
and cardiology consultations were normal. Sputum ARB was negative. The 
patient has been followed-up with these findings. PPD and ARB were still 
negative, and the skin lesions as well as lung findings spontaneously resolved 
after the follow-up period, therefore the primary diagnosis was considered to be 
sarcoidosis. The patient is still being followed-up without having any treatment. 
Conclusions: Based on a rare manifestation, thyroid involvement in a pa-
tient diagnosed with sarcoidosis on the basis of clinical and pathological 
findings, we intended to underline in this report that sarcoidosis may involve 
any organ and this possibility should always be taken into account while 
monitoring the patients. 
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Aim: Hypercalcemia, a common feature in sarcoidosis, is due to the excessi-
ve production of a Vitamin D metabolite, 1.25 (OH) 2D. Vitamin D efficiency 
in sarcoidosis though may not be appropriate. The purpose of this study 
was to assess Vitamin D levels in a sarcoidosis out-patient clinic compared 
to a mixed respiratory out-patient clinic population. 
Material and methods: 64 sarcoidosis cases and 53 control cases with 
other than sarcoidosis respiratory diseases, matched for age and sex, 
were prospectively included in the study. Serum Vitamin D, 1.25 (OH) 
2D, albumin, calcium, angiotensin converting enzyme were measured. 
Vitamin D was defined as deficient when < 20 ng/mL and insufficient 
when < 30 ng/ml. Clinical parameters for sarcoidosis cases were recorded. 
Results: Overall 41/64 (64%) of sarcoidosis subjects had low Vitamin D 
levels. They were more likely to exhibit Vitamin D deficiency (39%) or 
normal Vitamin D levels (36%) than controls (p = 0.018). Vitamin D de-
ficiency in sarcoidosis Group was associated with African-American race 
and radiological stage I disease. Regression analysis identified African-Ame-
rican race as the only significant factor predicting Vitamin D deficiency 
in sarcoidosis (p = 0.034). An inverse correlation between ACE and Vita-
min D levels marginally insignificant was noticed (p = 0.052). 1.25 (OH) 
2D was significantly elevated in sarcoidosis cases compared to controls. 
Conclusions: Vitamin D deficiency is prevalent in sarcoidosis. Severe Vitamin 
D deficiency is more prevalent in sarcoidosis patients than in patients suffering 
from other respiratory diseases. Among sarcoidosis patients, African-Americans 
are mostly in danger for hypovitaminosis D and should be monitored closely. 
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Introduction: Smoking related interstitial fibrosis (SRIF) was recently 
described as a distinct form of hyalinized interstitial fibrosis associated 
with emphysema and respiratory bronchiolitis. The diagnosis is often for-
tuitous and is not usually associated with significant respiratory symptoms. 
Functionally these patients may present obstruction and mild to moderate 
decrease DLCO. The most typical radiological findings in chest HRCT are 
well delimited subpleural emphysema, predominantly in middle and upper 
regions, associated with ground-glass opacities (GGO) and reticulation. The 
authors describe three cases of patients diagnosed with SRIF. 
Case 1: 49 years old man, mechanic, smoker, asymptomatic, attended 
the ILD outpatient clinic due to radiological features (micronodules and 
GGO). For suspected DIP went through bronchoalveolar lavage (BAL) and 
transbronchial cryobiopsy (TBC), which revealed histological findings 
compatible with SRIF. 
Case 2: 55 years old man, construction worker, smoker, asymptomatic, was 
sent to ILD clinic due to radiological features (emphysema, fibrosis and 
peripheral GGO). For suspected non-specific interstitial pneumonia, BAL 
and TBC were held, revealing findings consistent with SRIF. 
Case 3: 60 years old man, tiler, smoker, with occasional exposure to birds, 
was referred due to blood-streaked sputum. The chest HRCT suggested 
features of RB-ILD and DIP pattern. BAL and TBC were performed, sho-
wing SRIF features. 
Discussion: The authors wish to illustrate a distinct entity that needs to be 
recognized owing to a variable pathophysiology and prognosis, although 
the real natural history of SRIF is not full acknowledged. 
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Introduction: Tumor necrosis factor-alpha (TNF-a) inhibitors are re-
garded as the third-line therapy in sarcoidosis, the first choice gen-
erally being infliximab. To date, data regarding response to adali-
mumab in sarcoidosis patients intolerant to infliximab are lacking. 
The objective of this retrospective observational study was to establish if 
adalimumab could achieve stabilization or improvement of the disease in 
refractory sarcoidosis patients who developed intolerance to infliximab. 
Material and methods: Sarcoidosis patients referred to St. Antonius Inter-
stitial Lung Diseases Center of Excellence, Nieuwegein, The Netherlands, 
between January 2008 and April 2015 who switched from infliximab to 
adalimumab were included. Changes in organ function, inflammatory 
biomarker levels, and adverse events were retrieved from medical records. 
Results: Out of 142 infliximab treated patients, 18 (13%) had to discontinue 
treatment due to antibody formation or severe adverse events and switched 
to adalimumab therapy. Organ function improved in 7 patients (39%), 
was stable in 6 patients (33%), and worsened in 5 patients (28%) after 12 
months of treatment or after 6 months if evaluation after 12 months was 
not available (n = 4). In none of the patients biomarker levels of soluble 
interleukin-2 receptor (sIL-2R) deteriorated. Median decrease in sIL-2R 
was 3614 pg/mL. Most reported adverse event was infection (n = 10). 
Conclusions: Adalimumab is an effective alternative for patients intolerant 
to infliximab. The switch to adalimumab achieved clinical improvement in 
39% and stabilization in 33% of patients intolerant to infliximab. Further 
research is needed to develop guidelines on how to use adalimumab for 
sarcoidosis in terms of dosing regimen. 
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Introduction: A polymorphism in the MUC5B gene (rs35705950) is associ-
ated with susceptibility to fibrotic idiopathic interstitial pneumonias (IIP). 
MUC5B is a gel forming mucin and a major component of airway mucus. 
ABSTRACTS
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Aberrant function or regulation of mucins is possibly an important com-
ponent of mucosal infectious and inflammatory diseases. We investigated 
MUC5B protein levels in bronchoalveolar lavage fluid (BALf) in different 
forms of IIP and connective tissue disease associated interstitial pneumonia 
(CTD_IP). Furthermore, we assessed if MUC5B genotype influences BALf 
characteristics in IPF. 
Material and methods: MUC5B levels were measured in 72 IPF, 24 FIP, 24 
iNSIP, 20 CTD_IP patients and 52 controls. MUC5B was measured in BALf 
supernatant by ELISA. From IPF patients we collected smoking behaviour, 
age and lungfunction at diagnosis. 
Results: MUC5B BALf levels were significantly higher in IPF, FIP, iNSIP and 
CTD_IP compared to controls. There were no significant differences seen 
between the diseases. MUC5B levels correlated with DLCO% predicted in 
IPF patients at diagnosis (r = −0.45; p = 0.001), the higher MUC5B, the 
lower DLCO% predicted. BALf MUC5B levels were significantly higher in 
ever smokers than in never smokers in IPF. MUC5B BALf levels were not 
dependent on the MUC5B rs35705950 genotype in controls or IPF. In IPF, 
MUC5B minor allele associated with significantly lower count of neutrophils 
(p < 0.01) and eosinophils (p = 0.01) in BALf. In controls no correlation 
between BAL cell profiles and the polymorphism was found. 
Conclusions: IPF BAL cell profiles show that MUC5B minor allele carriers 
have lower inflammatory cell counts and might therefore be less prone 
to infections. 
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Airway-centered interstitial fibrosis (ACIF) is a new and rare interstitial 
lung disease (ILD) of unknown cause characterized by chronic cough and 
progressive dyspnea; history of inhaled exposure; propensity for women; 
occurrence in middle age; progressive peribronchiolar distribution of inter-
stitial inflammation and fibrosis with bronchiolar metaplasia distinct from 
any form of ILD or idiopathic interstitial pneumonia (IIP). The majority 
of patients are non-responsive to corticotherapy with poor prognosis. We 
describe 2 female patients, 65 and 66 years old, presenting with chronic 
dry cough and progressive dyspnea. Both non-smokers, farmers and with 
a history of inhaled exposition to birds. Chest radiographs revealed diffuse 
reticulonodular infiltrates and bronchial walls thickening. ChestCT showed 
reticular fibrosis and ground glass infiltrates across the pulmonary fields 
in one and sparing the upper on the other. Bronchoalveolar lavage showed 
a small increase in lymphocytes/neutrophils in one, the ratio CD4/CD8 < 
1 in both. The diagnosis was made by surgical biopsy revealing pericen-
trilobular lesions and linfoplasmocitary infiltrate compatible with ACIF. 
Both patients began systemic corticotherapy for 12 months. In one case 
the disease progressed with worsening symptoms, pulmonary functional 
tests and CT imaging even after starting combined imunosuppression 
with Azathioprine. The other patient improved with less symptoms and 
decreased area of disease on the CT image. These 2 cases presented similar 
clinical, radiological and pathological features as most of the few cases 
reported in literature. Our patients were non-smokers but were exposed 
to birds. The evolution varied with one improving after therapy and the 
other progressing even after combined imunosupression. 
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Introduction/aim: Sarcoidosis is a multisytem disease with unknown etio-
logy. Lungs are mostly affected. Lymph nodes, eye and skin involvements 
are seen according to the order of frequency. Other organ involvements 
are seen rarely. We aimed to take attention of diagnosis and treatment 
problems in sarcoidosis cases with rare organ involvement followed in 
sarcoidosis outpatient clinic. 
Material and methods: 651 cases followed in sarcoidosis outpatient clinic 
were examinated retrospectively. Data of patients with sarcoidosis have 
rare organ involvement were gained. 
Results: Eleven rare organ involvement was present in 10 patients (neuro-
sarcoidosis (Guillain-Barre syndrome (GBS) ), Bone marrow (BM), Thyroid 
(T), heart (H) (n = 2), gall bladder (GB), nodular splenic involvement (S) 
(n = 2), stomach/liver (S/L) (n: 2): musculoskeletal (M) ). Nine cases were 
stage 1, one case was stage 2. The pulmonary diagnosis of cases were 
histologically except GBS (bronchial biopsy (n = 3); medistinoskop (n 
= 5) ) wedge resection (n = 1) ). The diagnosis of extrapulmonary organ 
involvement was by histopathological (BM, T, GB, M, S/L) and radiologi-
cally. hypercalcemia (n2), eye (n2), and skin (n = 2) involvement were 
obtained other than rare organs involvements. Treatment was began in 
four patients have life-threatening organ involvements (GBS, H, BM, S/L). 
Treatment has been completed in 2 patients with cardiac involvement. 
Patients still follw-up with no symptom. 
Conclusions: Some Extrapulmonary involvement in sarcoidosis have a poor 
prognosis. Early diagnosis of EPS and prompt initiation of corticosteroid 
therapy with or without other immunosuppressants is crucial. 
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Introduction: The diagnostic classification “possible idiopathic pulmonary 
fibrosis (IPF) ” is characterised by an inconsistent usual interstitial pneumo-
nia (UIP) pattern on HRCT-scan and a UIP pattern in surgical lung biopsy. 
Therapeutic management in patients with “possible IPF” is challenging. 
The clinician must choose between either immunomodulatory agents or 
anti-fibrotic agents, but evidence is lacking. 
Material and methods: A multi-centre cohort of 59 patients with “possible 
IPF” treated with prednisone were retrospectively analysed. Prednisone star-
ting dose was 0.5 mg/kg/day and tapered to 0.15 mg/day/kg in six months. 
Patient demographics and serious adverse events (SAEs), defined as death 
and hospital admissions, were collected. Forced vital capacity (FVC) before 
start of therapy, baseline (start of therapy) and six months after start of 
therapy were evaluated. 
Results: In 59 prednisone treated “possible IPF” patients, 22% had a SAE: 
twelve in the first three months on prednisone > 0. 3 mg/kg/day and two 
during the last three months on < 0. 3mg/kg/day prednisone. Patients had 
a mean decline of 8. 7% FVC before treatment and a further mean decline 
of 21% after treatment (n = 32; p = 0.018). The majority of patients were 
non-responders (69%) with FVC > 5% decrease or death within six months 
from baseline. Six former smoking patients with an additional histopatho-
logical desquamative interstitial pneumonia (DIP) component besides UIP, 
were responders with a mean increase of 6% FVC. 
Conclusions: Patients with “possible IPF” demonstrated accelerated FVC 
decline and high incidence of SAEs during high dosed prednisone treat-
ment. Presence of concomitant DIP histopathological pattern is associated 
with responsiveness to prednisone treatment. 
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Introduction: Vasculitis are a Group of diseases that cause necrosis and 
inflammation of the blood vessel wall which eventually culminates in 
it’s destruction. 
Case: 59 years male, chainsaw operator, ex-smoker, history of alcoholism, 
gout and anemia. Treated with Iron, pantoprazole and allopurinol. Observed 
in the ER by nausea, vomiting and mild peripheral edema for 15 days and 
epigastric pain with hemoptysis in the latter 24 hours. Physical examina-
tion: uremic breath, mucocutaneous pallor and mild edema to the ankles. 
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Afebrile, eupneic and normotensive. Cardiac auscultation and pulmonary 
unchanged. Analytically with anemia, acute kidney injury, PCR 1 and 
metabolic acidosis with partial respiratory failure. Urine II with protei-
nuria, erythrocyturia and glycosuria. Chest radiograph revealed bilateral 
alveolar pattern in the lower 2/3. Performed hemodialysis and empirically 
started methylprednisolone, cyclophosphamide and plasmapheresis. Next 
days without improvement in renal function but resolution of respiratory 
complaints. CT-Thorax showed interstitial densification and mediastinal 
lymphadenopathy and bilateral pleural effusion. Respiratory function 
test with DLCO 77. Kidney ultrasound revealed attenuation of the normal 
parenchymal-sinus differentiation in the left kidney. Renal biopsy showed 
crescentic pauci- immune necrotizing glomerulonephritis. Analytically 
with positivity for anti-MPO. Discharged medicated with cyclophospha-
mide 50 mg id, prednisolone 60 mg id at weaning. Outpatient observed 
in the 3rd month after discharge: no respiratory symptoms and CT-Thorax 
control without parenchymal changes. DLCO 71. Held switch to azathio-
prine 100 mg. 
Conclusions: Systemic necrotizing vasculitides correspond to the majority 
of cases of diffuse alveolar hemorrhage of autoimmune cause. The sero-
logical study and renal biopsy are crucial for the differential diagnosis. 
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Introduction: Sarcoidosis is a granulomatous inflammatory disease of 
unknown etiology, genetic, infectious and environmental factors have 
been proposed to induce. Silicosis has been suggested to increase rates of 
autoimmune diseases as well. In present study, we hereby report 8 cases 
of sarcoidosis who have silicosis secondary to organic dust inhalation. 
Case: The study is conducted in a teaching hospital reference center for 
chest diseaes. Out of 616 sarcoidosis patients, who are being followed in 
our sarcoidosis outpatient clinic, 8 cases having inhalational dust exposure 
to silica crystalline were recorded retrospectively. All cases were male and 
the mean age was 40 (24−56). One case was asymptomatic whereas short-
ness of breath, cough and chest pain were the most common symptoms. 
Three patients were never smoker. Chest radiograms were staged as 3 in 
5 cases. All cases had bilateral nodules, bilateral hilar and mediastinal 
lymphadenopathy in chest CT. One case had restriction in spirometry, 
ACE was high in 3 cases. Diagnosis was made by mediastinoscopy (n = 
6), mediastinoscopy and lung biopsy (n = 1), gallium scintigraphy (n = 1). 
The median follow-up duration was 47 months. Radiological progression 
was recorded in one case whereas others remained stable. 
Conclusions: Coincidence of silicosis and sarcoidosis may suggest that 
there could be a common pathogenesis. Occupational history is impor-
tant in sarcodiosis and silicosis patients’ may need assessments from this 
perspective as well. 
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Introduction: Follicular bronchiolitis is a  rare disease characterized by 
hyperplastic reactive lymphoid follicles and germinal center formation 
in the bronchioles wall histologically. It may be idiopathic or secondary 
to some causes such as connective tissue diseases, immunodeficiencies, 
malignancies, hypersensitivity or infection. We report a case with follicular 
bronchiolitis in order to discuss the diagnosis and treatment. 
Case: A 57 year-old male patient was admitted to our clinic with sputum 
and fever continued for 6 months. He had been diagnosed as pnemonia 
and used antibiotics for 3 times in the last 6 months. He had smoked 50 
pack/years, was fashion designer, was born and raised in Istanbul and 
had no other disease. Bilateral reticulonodular infiltrates significant in 
lower zones were detected on chest radiograph. On Chest CT, tree-in-bud 
signs and micronodules were detected. Sputum and bronchoscopic lava-
ge samples did not yield mycobacteria or any other infectious agent. For 
definitive diagnosis, he underwent surgical biopsy and was diagnosed as 
follicular bronchiolitis. No etiologic factor was found in the detailed hi-
story. Clarithromycin and steroid treatment was started. In the first month, 
clarithromycin treatment was discontinued due to clinical improvement. 
In the fourth month, radiological right lung regressed significantly whe-
reas a little progression was detected in the left lung. Clarithromycin was 
re-added to steroid therapy. ntinued. The patient is in 4 months of therapy 
is still in our follow- up. 
Conclusions: Follicular bronchiolitis has been reported as case presenta-
tions in the literature. Treatment is planned due to underlying cause but 
there is no treatment protocol for idiopathic situations. Close monitoring 
of these patients is important. 
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Organizing pneumonia and pulmonary fibrosis secondary to 
Sjögren Syndrome: case report
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Introduction: Sjögren syndrome is a  systemic chronic inflammatory 
disorder associated with lymphocytic infiltration of exocrine glands. In 
addition, multiple extranglandular features may develop, including pul-
monary involvement. 
Case: 62 years old female, unemployed, non-smoker, with history of right 
mastectomy, hypothyroidism, depression and osteoporosis. Treated with 
alprazolam, venlafaxine, levothyroxine, alendronic acid, colecalciferol. 
Patient referenced with dyspnea complaints to moderate exertion, wheezing 
and asthenia in 2010, also xerophtalmia. Physical examination showed mild 
hypertrophy of right parotid. Thoracic radiography with lower bilateral reti-
cular pattern and HRCT with interstitial pattern and ground glass opacities 
more evident in the middle lobe and lower lobes. Analyzes with positive 
ANA 1/1280 granular pattern, FR and anti-SSA. Respiratory functional 
study with restrictive pattern. No changes in blood gases. Transthoracic 
biopsy performed which revealed organizing pneumonia but the patient did 
not want to start treatment at this time. Sent also to a Rheumatologist who 
made diagnosis of primary sjögren syndrome. At 6 months follow-up, the 
patient maintained respiratory complaints and accepted start treatment with 
prednisolone 20 mg for 1 year, with improvement of respiratory complaints. 
Reevaluation HRCT at 2012 showed progression to pulmonary fibrosis 
(craniocaudal gradient and subpleural space achievement) with diffuse 
ground glass. In 2015, further deterioration of respiratory complaints with 
hypoxemia and HRCT showed worsening fibrosis. Started prednisolone 50 
mg, azathioprine 50 mg id and LTOT, maintaining follow-up at this time. 
Conclusions: Sjögren’s syndrome is a common auto-immune disease. The 
respiratory system is frequently involved with 10% of the patients deve-
loping a clinically significant lung disease. 
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Introduction: Sarcoidosis is an inflammatory disorder characterised by 
granuloma infiltration of two or more organs. Exclusion of other aetiologies, 
mainly infectious, autoimmune and neoplastic is mandatory in a demanding 
process as demonstrated in this case report. 
Material and methods: Review of clinical file and scientific literature. 
Case: A 59 year old healthy non-smoker female was admitted for investi-
gation of an L2 fracture with lytic lesions after a low energy trauma. No 
previous infections, environmental exposure or travel history were determi-
ned. Apart from lower back non-irradiating pain, physical examination was 
unremarkable. A tomography revealed multiple organ infiltration: lungs, 
liver, lytic bone lesions (vertebrae, sternum, iliac and ribs) associated with 
cervical, mediastinal and abdominal lymph nodes. Biopsies of cervical 
lymphadenopathies and iliac bone showed chronic inflammatory tissue 
with granulomas. Neoplastic aetiology was excluded after colonoscopy, 
endoscopy, mammogram, thyroid ultrasound and complete gynaecologic 
and dermatologic studies. Interferon Gamma Release Assay, blood cultures, 
infectious and autoimmune serologies excluded other causes of systemic 
granulomatous disease. Bronchoalveolar lavage cultures were negative and 
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CD4/CD8 ratio was technically undeterminable. Treatment with cortico-
steroids was started pending radiologic revaluation. 
Conclusions: The authors present a case of widespread sarcoidosis with 
pulmonary, lymph nodes, liver and bone involvement. Bone involvement 
can be seen in < 10% of sarcoidosis patients, most commonly in the form 
of cystic osteitis. Vertebral lytic lesions are noted in < 1% of extrapulmo-
nary sarcoidosis making this a rare manifestation of sarcoidosis. Long term 
follow up and positive response to corticosteroids will be determinant to 
absolutely exclude alternative diagnosis. 
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of anti-synthetase syndrome
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Introduction: The usual clinical manifestations of anti-synthetase syndrome 
are myositis, fever, polyarthritis, raynaud phenomena and interstitial lung 
disease. Immunologically it presents with positive anti-tRNA synthetase 
antibodys. This case report shows an unusal manifestation of this syndrome. 
Material and methods: We made a summary of the case report, including 
diagnostic exams. 
Results/case report: 58-year-old woman, with a clinical background oh 
high blood pressure and cerebral ischemic event. ANA autoantibodies 
always positive in previous analysis, without autoimmune disease criteria. 
Admitted for sense of fatigue, effort dyspnea, dry cough and fever. Pulmo-
nary auscultation showed bibasal crepitations. Chest radiography: bibasal 
condensations; blood analysis: neutrophilic leukocytosis, PCR 6. 82 mg/dL. 
Clinically improved after antibiotherapy. Readmitted 2 weeks later for the 
same symptoms, hypoxemic (pO2 59 mm Hg), when she performed thoracic 
CT-scan: bibasal consolidations with air bronchogram; pulmonary-function 
tests: small-airways obstrution; positive anti-EJ antibody; bronchofibrosco-
py with normal macroscopic aspect, bronchoalveolar lavage with 700cells/
mm3, 70% linfocites (CD4/CD8 = 0.22), 24% macrophages, 6% eosinophi-
les, 0% neuthrophiles, BK search was negative; Normal eletromyography. 
The patient started corticotherapy (prednisolone 1mg/Kg/day) with rapid 
clinical improvement. Thoracic CT-scan after 3 month on corticotherapy 
showed only some pulmonary fibrosis.
Conclusions: Though anti-synthetase syndrome is a systemic disease, it may 
present with isolated pulmonary involvement, which is the main prognostic 
determinant in this patients. Autoantibodies may represent a precious help 
on the diagnostic aproach of patients with isolated interstitial lung disease. 
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Introduction: Non-specific interstitial pneumonia (NSIP) is the second most 
common pattern of idiopathic interstitial pneumonias. Although natural 
history of NSIP is not yet fully established and its evolution depends on 
the underlying etiology, NSIP usually comprises a good prognosis. 
Aims: Characterization of patients with NSIP. 
Material and methods: Retrospective analysis of patients with NSIP, 
encompassing etiology, clinical, functional and imagiologic evaluation, as 
well as evolution characterization. 
Results: Included 57 patients, with a mean (± SD) age of 60 (± 12) years 
and 78. 9% female. The majority (54. 4%) was non-smoking. Possible 
etiologies for NSIP pattern were related in most patients (61. 4%, n = 35) 
with CTD and in the remaining with drug toxicity (n = 10), chronic HP (n 
= 10) and 2 cases were considered idiopathic. Regarding CTD patients, 13 
had systemic sclerosis (SSc), 10 rheumatoid arthritis, 4 dermatomyositis/
polymyositis, 3 Sjögren’s syndrome, 3 mixed connectivite tissue disease 
and 2 systemic lupus erythematosus. Drugs associated with NSIP were 
statins (n = 7) and metformin (n = 3). At baseline functional assessment: 
mean (± SD) FVC of 97 (± 22.6)%, FEV1 of 97.3 (± 20.1)% and TLC of 93.2 
(± 184)%. The majority of patients (n = 41) had decreased DLCO (65.3 
(± 20.2)%). Between CTD patients, there were lower values of FVC in 
SSc (p < 0.05). In 47.4% of NSIP cases, immunosuppressive therapy was 
introduced. Only 5 patients (10.2%) died during the follow-up (in 2cases 
cause of death was not related to NSIP). 
Conclusions: In this series of cases with NSIP, it was found that the CTD 
were the main responsible etiology, and few cases were idiopathic. Major 
functional impairing was reflected in a decrease in DLCO. 
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Aim: Examination of AL apoptosis frequency in sarcoidosis, with relation to 
the clinical presentation, i. e. in patients subdivided into Loefgren’s Syndrome 
(LS), chronic stable sarcoidosis (SC) and chronic progressive sarcoidosis (PS). 
Material and methods: BAL of 103 sarcoidosis patients and 17 controls 
was examined for: a) AL apoptosis in flow cytometry (sub-G1 peak of cell 
cycle); b) TUNEL assay; c) AL staining for BCL2 family, caspase-3, and death 
receptors/ligands (Fas, DR3, DR4, TNFR1, FasL, TRAIL); d) cytoimmunology. 
Additionally, in 7 PS patients AL apoptosis was revaluated after 3-6 months 
of systemic corticosteroid treatment. 
Results: AL apoptosis rate was lower (p < 0.05) in LS and PS, but not in CS, 
than in controls (e. g. sub-G1 peak for LS: 0.3 ± 0. 2%, CS: 0.8 ± 0.3%, PS: 
0.4 ± 0.4%, controls: 0.9 ± 0. 6%, median ± SEM); parallel TUNEL data 
were obtained. AL in sarcoidosis was characterized by lower expression 
of TNFR1 (significant for LS and PS), FasL and TRAIL (significant for all), 
caspase-3 (significant for LS). Steroid treatment in PS patients resulted in 
remarkably increased percentage of apoptotic AL (incl. cases of “mitotic 
catastrophe” in cell cycle) and decline of BCL2+ cells. Moreover, AL apop-
tosis rate in sarcoidosis was negatively correlated with BAL lymphocytosis 
(Rs = –0.49, p < 0.01) and AL activation (percentage of CD3+HLA- DR+ 
cells: Rs = –0.28, p < 0.002). 
Conclusions: AL apoptosis rate in sarcoidosis is declined only in active forms 
of the disease. The possible mechanisms include high expression of BCL2 and 
low of death receptors and their ligands. AL infrequent apoptosis is responsi-
ble for development of lymphocytic alveolitis in the disease. Corticosteroid use 
benefit in chronic progressive sarcoidosis induces high rate of AL apoptosis. 
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Introduction: Antigen presenting cells (APC) participate in ILD by priming 
specific T cells, regulating inflammatory response and disease outcome. 
Local APC system includes dendritic, Langergans and B cells, as well as 
alveolar macrophages. Interestingly, we have previously shown that AL 
produce APC-linked cytokine, IL-27. There is a question, if T cells possess 
a local ability to present antigens. 
Aim: Immunotyping of APC markers on lymphocytes (AL) harvested by 
BAL from ILD patients. 
Material and methods: AL originating from BAL carried out in sarcoidosis, 
PS, idiopathic pulmonary fibrosis, IPF, nonspecific interstitial pneumonia, 
NSIP, exogenous allergic alveolitis (EAA) and controls (n = 33, 17, 10, 9, 7) 
were immunotyped for HLA-DR, CD80, CD86 (costimulatory B7 molecules) 
CD83 and CD1a with use of flow cytometry. 
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Results: AL, Th and Tc cells, in similar extension, express mostly HLA-DR, 
CD80 and/or CD86. The HLA-DR+CD80+CD86+ coexpression occurs in 
AL of all tested Group s and varies from 0 to 16% of CD3+ cells. It is in-
creased in IPF, as compared to controls, while PS and EAA is characterized 
by significantly lower percentage of CD80+CD86+ cells (e.g. CD4+HLA
-DR+CD80+CD86+: 2.6 ± 1. 4% in PS and 1.7 ± 1.1% in EAA as compared 
to 8.3 ± 3.7% in controls; median SEM, p < 0. 05). AL CD80+CD86+ 
percentage was negatively correlated with BAL lymphocytosis and number 
of AL with T effector phenotype (CD3+CD27-CD28-); there was no relation 
to patients clinical data, including lung function test results. 
Conclusions: 1. AL phenotype suggests T cells to be active in ILD as APC. 
2. Frequency of AL APC-linked phenotype is declined in ILD patients with 
high BAL lymphocytosis. 
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Introduction: The aim of this study was to determine the use of the lipid 
profile of patients with sarcoidosis and compare it with healthy subjects. 
We assume that lipid profile of serum in sarcoidosis differs from the control 
subjects lipid profile. 
Material and methods: Serum was collected from 9 patients with II stage of 
sarcoidosis and 5 control subjects. In our studies proton nuclear magnetic 
resonance (NMR) spectroscopy of lipid extracts was used. NMR spectra were 
collected using 400 MHz spectrometer and standard one pulse sequence. 
Lipids were extracted from serum before analysis using modified Blight 
and Dyer method and dissolved in deuterated chloroform. Thirty four NMR 
signals of lipid compounds were analyzed. Partial least square discriminat 
analysis (PLS-DA) with Pareto scaling were used to analyzed lipid profile. 
Results: Univariate t-test analysis show significant differences in NMR signals 
of both esterified and free cholesterol and fatty acids (p < 0.05). For analyzing 
lipid profile discriminant analysis was applied. Obtained PLS-DA model con-
sisted of three components and very good explain the data and also predict 
the data. Discriminant analysis correctly classified patients according to their 
Group s for 100% of sarcoidose and 100% of control. Lipidomics indicated 
significant differences in phosphatidylcholine, triglycerides, fatty acids 
and sphigomyelin two unassigned compounds (4. 94ppm, 514ppm) levels. 
Conclusions: Lipidomics is able to differentiate sarcoidosis patients and con-
trol subjects based on lipids profile of serum. Our investigation demonstrated 
that this technique can offer also insight into the lipid states of sarcoidosis. 
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The case report presents 33-year-old female patient who had chronic bi-
lateral lymphadenopathy with pulmonary involvement sub forma small, 
scattered granuloma and patchy area of peripheral fibrosis, visible in 
chest CT. Before 2013 the patient was misdiagnosed as sarcoidosis, luckily 
without treatment due to lack of recommendation (mildly visible changes 
in PFT, with no extrapulmonary manifestations). 
Firstly, the patient was suspected of persistent pulmonary sarcoidosis, 
without spontaneous remission. 
Due to worsening in pulmonary function test, which showed mild restric-
tion with lowered DLCO the patient was admitted to our centre — with 
ILD focused unit. After comprehensive examination, it turned out that 
despite lung disease, the only malady is BMI below 17, than she was 
tested to Ig M, G, A levels — which were extremely lowered. To reassure 
our team’s suspicious, we perform VATS. Histopathological sample was 
ultimately classified as not typical sarcoid granuloma, but poorly formed 
granuloma like in inflammatory response linked to immune deficiency 
syndrome. Having achieved those results, and excluding others causes 
we started treatment with immunoglobulin supplementation — with total 
regression of the disease in the thorax. 
CVID as a primary immune deficiency (PID) syndromeis associated with 
usually early respiratory tract involvement, and is diagnosed in childhood 
rather, due to recurrent respiratory infections or gastric manifestation. But 
being aware of PID delayed manifestations, as well as sarcoidosis linked to 
IgA deficiency syndrome, nowadayswe should put an extreme attention to 
perform proper diagnosis of pulmonary changes including rare disorders. 
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Introduction: Anti-DFS70 antibodies, corresponding to the dense fine spec-
kled ANA indirect immunofluorescence pattern in HEp-2 substrates, have 
been observed in chronic inflammatory conditions, cancers and even in 
healthy individuals but only in a small percentage of patients with systemic 
autoimmune rheumatic diseases (SARD). Aim of this study: To investigate 
the frequency of serum anti- DFS70 in patients with ILD and a possible 
correlation with ANA status and the presence of CTD. 
Material and methods: 113 patients with ILD (70 IPF and 43 NSIP), 50 
healthy controls and 36 scleroderma patients as negative control were 
studied. 14 patients had or developed CTD during 24 months of follow up 
(1 IPF and 13 NSIP). Serum anti-DFS70 at baseline was measured by ELISA 
(Medical and Biological Laboratories Co., Ltd., Japan), and the cut-off for 
positivity was set at 400 U/mL. 
Results: ANA were positive in 20/43 (47%) NSIP patients and 22/70 (31%) 
IPF patients. All healthy controls were ANA negative and 36% anti-DFS70 
positive. All scleroderma ILD patients were ANA positive and only 6% 
anti-DFS70 positive. Anti-DFS70 were positive in 7/43 (16%) NSIP patients 
and 15/70 (21%) IPF patients. Among ANA (+) ILD patients (42), only 6 
(14%) were anti-DFS70 positive and among ANA (−) ILD patients (71), 
16 (23%) were anti-DFS70 positive. 8/36 (22%) of ILD patients with ANA 
(+) and anti-DFS70 (−) and 1/6 (16%) of ILD patients with ANA (+) and 
anti-DFS70 (+) had or developed CTD over time, all of them had NSIP. 
Conclusions: Anti-DFS70 positivity is more frequent in ANA negative 
healthy subjects. ANA positivity combined with anti- DFS70 negativity 
seems to be associated with CTD in NSIP patients. 
P40
Diagnostic usefulness of [18f]FDG-PET/MRI in patients with 
sarcoidosis: pilot study 
Beata Kuklińska1; Dorota Jurgilewicz2; Janusz Myśliwiec2; 
Małgorzata Mojsak2; Bożena Kubas3; Marcin Hładuński2; Anna Amelian2; 
Robert Mróz1
1II Department of Lung Diseases, Medical University of Bialystok; 2Nuclear 
Medicine Department, Medical University of Bialystok; 3Radiology Depart-
ment, Medical University of Bialystok
Introduction: PET/MRI is a new hybrid imaging technic which enables - 
simultaneous whole body molecular magnetic resonance and metabolic 
positron emission tomography made in one study. 
Aim: The purpose of this study is the evaluation of the impact of [18F]
fluorodeoxy-d-glucose (18F-FDG) positron emission tomography (PET) /3T 
whole body magnetic resonance (MR) hybrid use on diagnosis and staging 
of sarcoidosis patients. 
Material and methods: FDG-PET/MR was performed in 26 patients (F/M: 
10/16, mean age: 45 (25−69), with computed tomography (CT) diagnosed 
and histologically confirmed pulmonary sarcoidosis. PET scans were 
obtained 60 min after injection of 295  ±  45 MBq [18F]FDG). All patients 
underwent  18F-FDG PET/MR and CE-MRI (Contrast Enhanced Magnetic 
Resonance) of the thorax at 3T in the prone position with proper MR se-
quences. Quantitative assessment was performed by calculation of SUVMAX. 
Disease staging was performed independently by two nuclear medicine 
and one radiology specialist. 
Results: PET/MRI confirmed metabolically active disease in the lesions 
localized by CT in all patients. Fifteen (57%) patients were classified as 
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phase I, and 11 (43%) as phase II pulmonary sarcoidosis. Increased 18F-FDG 
uptake in PET/MR study, with SUVMAX: 2.43−9.00, as a new additional 
metabolically active foci were found in: abdominal lymph nodes in 8 (30%) 
patients, cardiac left ventricule — in 1 (3%), musculo-sceletal system in 1 
(3%) patient. Additionally, in seven patients with nonspecific neurological 
symptoms slight CNS changes were found on MR images. 
Conclusion: FDG-PET/MRI might be a promising tool in early and compre-
hensive diagnosis of sarcoidosis relevantly influencing decision-making 
process. 
P41
Risk factors for increased mortality in sarcoidosis
Anastasios Kalianos1; Konstantinos Tzimopoulos2; Aikaterini Kavada1; 
Konstantina Aggeli3; Helias Gialafos1; Angeliki Rapti1
1Sotiria Hospital, Athens, Greece; 2Sotiria Hospital-Ippokratio Hospital, 
Athens, Greece; 3Ippokratio Hospital — Athens University, Athens, Greece 
Introduction: The mortality rate of the sarcoidosis is 5–10% however little 
are known for the parameters that estimate this rate. Aim to determine risk 
factors that could increase mortality of the disease. 
Material and methods: 122 patients (43 men, mean age 48.65 ± 13.3 
years) with biopsy proven sarcoidosis were studied retrospectively. Lung 
function tests including total lung capacity (TLC) and diffusion capacity 
(DLCO), surface electrocardiogram, cardiac ultrasound, 24-hour Holter 
monitoring, BNP and SACE were examined. Mean heart rate, maximum 
and minimum heart rate and time domain indices of heart rate variability 
(Standard Deviation of RR-SDRR, RMSDD, pNN50) were calculated from 
the 24 hour Holter while evidence of ventricular arrhythmias were noted. 
Cardiac sarcoidosis was detected if there were abnormal finding on cardiac 
ultrasound, ECG and/or holter and cardiac MRI. 
Results: During a median 58.89 ± 15.75 month follow-up, there were 10 
deaths (8.2%). 5 patients died due to cardiac and 5 due to other causes. 
Cardiac involvement was estimated in 40 patients (32.8%). TLC < 80% 
of the predicted was presented in 29 (23.77%) while isolated DLCO 
reduction was presented in 21 (17.21%) patients. In the multivariate 
analysis, standard deviation of all normal-to-normal RR intervals < or 
= 90 ms, TLC < 80%, DLCO < 80% of the predicted and the presence 
of cardiac involvement were found to be independent risk predictors of 
all causes mortality. 
Conclusions: Increased risk of mortality and cardiac death could be pre-
dicted in patients with sarcoidosis by evaluating the cardio-respiratory 
function. TLC and/or DLCO reduction, the presence of cardiac involvement 
and the standard deviation of RR intervals were independent predictors 
of all causes mortality. 
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Introduction: We have previously presented evidence that the polymor-
phism of the FCGR3A gene, encoding the receptor for Fc fragment of immu-
noglobulin G IIIa (FcgRIIIa) plays a role in the enhancement of circulating 
immune complexes (CIs) with the occurrence of mycobacterial heat shock 
proteins in patients with sarcoidosis (SA). The immunocomplexemia might 
be caused by decreased affinity of CIs to Fcg receptors, with the subsequ-
ently decreased receptor clearance by immune cells. In the present study 
we examined whether the polymorphisms of other related genes (FCGR2A, 
FCGR2C, FCGR3B) encoding other activatory Fcg receptors, could have 
a similar effect. 
Material and methods: Thus, we analysed polymorphism of FCGR2A, 
FCGR2C, and FCGR3B in 104 SA patients and 110 healthy volunteers 
using PCR-SSP. 
Results: Our study found significantly lower percentage of FCGR2A and 
FCGR2C with a concomitant increase of less functional variants of these 
genes in Stages I/II, than in Stages III/IV of SA. There was no aberration in 
FCGR3B allele/genotype frequencies. 
Conclusions: We conclude that the FCGR2A and FCGR2C polymorphisms 
may also contribute to immunocomplexemia present in SA. The assess-
ment of FCGR genes could become a tool in presaging a clinical course of 
sarcoidosis and in its personalized therapy. 
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Bronchial and peritoneal sarcoidosis in a 30 y/o asymptomatic 
woman: case report
Oskar Okuniewski1; Katarzyna Woźniak1; Anna Dubaniewicz1; 
Jan Słomiński1; Szymon Wojtylak2; Bartłomiej Rękawiecki1
1Department of Pulmonology, Medical University of Gdańsk, Gdańsk, 
Poland; 2Departament of Pathomorphology, Medical University of Gdańsk, 
Gdańsk, Poland 
Sarcoidosis (SA) is a multisystemic, granulomatous disease with unknown 
etiology. Infectious and non-infectious, genetic factors, as well autoimmu-
nity have been considered as potential etiologic causes. Pulmonary involve-
ment is the most prominent, however other locations are not infrequent. 
We have reported a case of a 30 years old Caucasian female, diagnosed with 
peritoneal sarcoidosis. The patient was asymptomatic, and was undergoing 
diagnostic procedures due to infertility. Transvaginal ultrasonography 
revealed non- characteristic changes localized proximal to the ovary and 
presence of a little amount of free fluid inside the peritoneal cavity. Due 
to subsequent high levels of serum CA-125 marker a suspicion of asymp-
tomatic ovarian cancer was made. Results of histological examination of 
samples obtained from a diagnostic laparoscopy showed non-caseating 
granulomas in the peritoneum of the abdominal cavity, ovaries, oviducts, 
uterine body, and large intestine. Tuberculosis and carcinoma were excluded 
as a potential etiology of these findings. HR-CT scan of lungs showed no 
pathology but a diagnostic fiberoscopy with biopsy of the wall of the bronchi 
showed presence of sarcoid granulomas. This case has a potential scientific 
as well as clinical value, as it describes a case of peritoneal sarcoidosis, 
which is an extremely rare extrapulmonary manifestation of the disease, 
without any parenchyma lung involvement. The elevated level of CA-125 in 
sarcoidosis is a subject, which deserves a further study on a larger number 
of patients, as it has already been reported in a few cases. 
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Influence of contrast enhancement CT and experience in chest 
imagining on the assessment of chest lymph nodes in sarcoidosis 
patients
Agnieszka Jarzemska1; Magdalena Sobocinska1; Bartosz Sobocinski2; 
Zbigniew Serafin2
1Regional Center of Lung Diseases, Bydgoszcz, Poland; 2Nicolaus Coperni-
cus University Collegium Medicum, Bydgoszcz, Poland 
Aim: The aim of the study was retrospective analysis of chest CT evaluations 
of 40 patients with sarcoidosis. 
Material and methods: Examinations consisted of non-enhanced (non-
CE) and contrast-enhanced (CE) acquisitions that were performed at the 
same time at each patient, using the same CT unit, CT protocol with the 
same team of radiologists (less and more experienced in chest imagining). 
Significance of differences in parametric data (lymph nodes diameters, 
levels) were tested using ANOVA. Concordance between observers regar-
ding of parametric data was determined using ICC, non-parametric data 
was assessed using Cohen’s κ. 
Results: A total analysis included 40 non-CE and 40 CE datasets for ANOVA 
analysis, 80 non-CE and CE datasets for comparisons between radiologists 
and residents. There were no significant differences between „ chest”radiolo-
gists and residents, apart from the dimension of the 4R node, but the number 
of affected node levels was found significantly higher when evaluated on 
CE images, within significant difference between all observers. 
Conclusions: The application of contrast medium has a limited influence on 
the quality of general assessment of the chest lymph nodes in sarcoidosis 
patients, regardless experience of the observer. The necessity of contrast 
enhancement for chest lymph nodes imagining is still debated due to its 
nephrotoxicity. With corresponding clinical data of sarcoidosis common 
recommendation for using contrast enhanced CT for evaluation chest lymph 
nodes seems to be weak. CT imagining is usually important to find the best 
place for EBUS provided biopsy which is visible good enough in non CE CT. 
Pneumonologia i Alergologia Polska 2016, vol. 84, Supplement III, pages 1–14 
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Age, forced vital capacity and anxiety sensitivity as predictors  
of dyspnea intensity in sarcoidosis
Pawel Holas1; Julia Szymanska2; Anna Dubaniewicz3; Malgorzata Farnik4; 
Agnieszka Jarzemska5; Marta Maskey- 
-Warzechowska6; Joanna Domagala-Kulawik6
1Warsaw University, Faculty of Psychology, Warsaw, Poland; 2Warsaw 
University, Faculty of Psychology, Warsaw, Poland; 3Medical University 
of Gdansk, Gdansk, Poland; 4Silesian Medical University, Katowice, 
Poland; 5Department of Pulmonology, Regional Lung Centre Bydgoszcze, 
Bydgoszcz, Poland; 6Medical University, Warsaw, Poland 
Introduction: Sarcoidosis is a chronic multisystem disease of unknown 
etiology. In spite of the high prevalence of depression and anxiety in sar-
coidosis, relatively little is established regarding the potential impact of 
psychological variables on respiratory symptoms reported in this disorder. 
Although every organ can be involved, the lungs are affected most often 
and dyspnea is one of the most frequents complaints in patients with 
sarcoidosis. There is some evidence that anxiety and anxiety sensitivity 
exacerbate dyspnea associated with pulmonary disease, but little is known 
about psychological factors contributing to dyspnea in sarcoidosis. The-
refore, the aim of the present study was to investigate factors predicting 
dyspnea severity in sarcoidosis. 
Material and methods: 110 patients (mean age 45. 3 years) were enrolled. 
They underwent spirometry and the following questionnaires: Hospital 
Anxiety and Depression Scale and Anxiety Sensitivity Index-3, MRC and 
items assessing demographic variables and symptoms. 
Results: Dyspnea intensity was found to be related with higher age, physical 
concerns subscale of ASI (ASI_ph) and with lower FVC. Linear regression 
showed that FVC predicts the dyspnea intensity as long as the model 
lacks ASI_ph variable. The whole model explained about 18% of MRC 
dyspnea intensity variance, with age and ASI_ph as significant predictors 
explaining 7. 51% and 6. 50% of dyspnea variance respectively and FVC 
as non-significant predictor. 
Conclusions: The finding that fear of physical sensations (ASI_ph) predicted 
more severe subjective dyspnea than FVC call for developing strategies to 
measure and reduce high levels of anxiety sensitivity to improve functioning 
in dyspneic patients with sarcoidosis.. 
P46
The role of PET in lung sarcoidosis: preliminary results  
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Introduction: In sarcoidosis the ability to unveil unsuspected and persisting 
inflammatory activity (granulomas) may add in patient evaluation. 18F-
fluoro-2-deoxyglucose (18FDG) positron emission tomography (PET) chest 
computed -tomography (CT) has been reported useful in the estimation of 
sarcoidosis activity. 
Aim: To investigate the role of 18FDG/PET/CT in the evaluation of intratho-
racic active disease and its relationship to functional and clinical findings 
in pulmonary-sarcoidosis-patients. 
Material and methods: Sarcoidosis patients referred to our department 
between 2012 and 2015 were prospectively investigated by chest x-ray, 
CT, pulmonary function testing and 18FDG/PET/CT in addition to systemic 
investigation. Results One hundred twenty four consecutive sarcoidosis 
patients, 49.1% treatment-naïve, a median age of 52 years, Scadding radio-
graphic stage 0, I, II, III, IV of 15.2/43.8/33/5.4/2.7, median FVC, Tiffeneau, 
DLCO, TLC predicted of 95.6%, 79.12%, 81%, 89.5% were studied. Female 
were 55.3% and no/ex-smokers 89.8%. Median diagnosis duration (IQR) 
was 2 years (0−8) and median follow-up (IQR) 13.5 (8−19) months. Acute 
and chronic disease was 51. 61 and 29.83% respectively. Based on 18FDG/
PET/CT, 15.9% had thoracic disease only, 5.6% extrathoracic disease 
only and 68.2% had both thoracic and extrathoracic disease. Concerning 
intrathoracic 18FDG/PET/CT findings, bilateral hilar, subcarinal, subaor-
tic lymph nodes and bilateral lung parenchyma were the most common 
sites of disease activity (61.3%, 52.4%, 32.35%, and 33.06% respectively). 
Pulmonary parenchyma active disease patients expressed lower FEV1, 
FVC, DLCO and TLC (p < 0.001, p = 0.001 p = 0.002 and p = 0.17) and 
presented more often cough (p = 0.045). 
Conclusions: 18FDG/PET/CT lung active disease was observed in 85% 
of patients and was associated with functional and clinical parameters. 
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Introduction: Comorbidities have an unfavorable effect on outcome of 
both myelodysplastic syndromes (MDS), and idiopathic pulmonary fibrosis 
(IPF). IPF is an irreversibly fibrotic disease and acute respiratory distress 
syndrome (ARDS) dramatically complicates its course. The constellation 
of both has been encountered in short-telomere syndromes with TERT or 
TERC germline mutations. 
Material and methods/aim: To examine clinical characteristics, genetic 
background, and outcome of a small cohort of pulmonary fibrosis-MDS 
patients. PF-MDS patients diagnosed in 2015 underwent genetic testing 
for TERT and TERC sequencing after written informed consent. Demo-
graphic, clinical, laboratory, genetic characteristics and survival were 
reported. 
Results: Five PF-MDS patients, 4 male, median age of 80-years, 60% ex-
smokers, FVC = 85. 65, TLC = 64.25, DLCO = 62.1% predicted, Ht% = 
33.9%, MCV = 105.6, WBC = 4250, PLTs = 171,000 were studied. IPF 
diagnosis predated MDS in 3. One patient presented refractory anemia 
(RA) and one RA with ring sideroblasts with low International prognosis 
scoring system (IPSS) score whereas 3 presented RA with excess blasts with 
intermediate-1, intermediate-2 and high IPSS scores respectively. TERT or 
TERC germline mutations were not identified. Two of 3 azacitidine-treated 
patients developed leukemia. All treated plus one untreated-patient (80%) 
succumbed to fatal ARDS upon IPF event during hospitalization for febrile 
infectious episode, 13 (9.75−14) months post-MDS-diagnosis and 9 (1−9) 
months post-MDS-treatment initiation. 
Conclusions: MDS and IPF may co-exist without TERT or TERC germline 
mutations in aged patients. Outcome may be precipitated by fatal ARDS 
upon IPF triggered by infections in patients with high IPSS-score necessi-
tating frequent hospitalizations and receiving aggressive myelosuppressive 
treatment. 
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Cyclooxygenase-2 and miR-16 expression in pulmonary 
sarcoidosis
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Introduction: Elevated COX-2 activity is associated with the development 
of chronic lung diseases, including sarcoidosis. It was confirmed, that COX-
ABSTRACTS
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2 is targeted by the miR-16 leading to downregulation of COX-2 expression 
by altering mRNA stability. This mechanism is claimed as a key posttran-
scriptional COX-2 regulation. 
Aim: The aim of the study was to examine expression pattern of  COX-
2 mRNA in relation to miR-16 expression in sarcoidosis patients. 
Material and methods: Expression evaluation of both: COX-2 and miR-16 was 
performed by qPCR method in bronchoalveolar lavage (BAL) cells and periph-
eral blood (PB) lymphocytes in sarcoidosis patients (n = 61) and control Group 
(n = 30). Analysis of COX-2 mRNA revealed down-regulation (RQ < 1) in 
BAL fluid and in PB lymphocytes in patients and in control Group s with 
insignificantly lower COX-2 expression in patients in BAL fluid (p > 0.05 
Mann-Whitney U-test) and significantly higher COX-2expression in patients 
in PB lymphocytes (p = 0.003 Mann-Whitney U-test). 
Results: Analysis of miR-16 expression in BAL fluid and PB lymphocytes 
revealed its upregulation (RQ > 1) in both biological material with insig-
nificantly higher expression of miR-16 in BAL fluid and PB lymphocytes 
in patients (p > 0.05 Mann-Whitney U-test). 
In total Group of sarcoidosis patients in BAL fluid we observed a trend towards 
negative correlation between COX-2 and miR-16 expression in patients with II-IV 
radiological stage (p > 0.05, r = −0.133 Spearman’s rang correlation test) and 
in patients with chronic form of disease (p > 0.05 R = −0.02 Spearman’s rang 
correlation test) with reduced expression of COX-2 in relation to miR-16. 
Conclusions: Results suggest that reduced expression of mRNA COX-2  in 
patients BAL fluid is associated with elevated expression of miR-16. Ex-
pression of COX-2 mRNA in patients with pulmonary sarcoidosis may be 
directly controlled by miR-16. 
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